Ara
Toplam kayıt 1, listelenen: 1-1
Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia
(CIG Media Group, 2020)
Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor ...